A retrospective analysis of clinical forms and age of onset of biallelic Huntington disease patients from an Argentinean Center
Objective: To compare AO and clinical presentation in Argentinean bi-allelic (BHD) patients, ie one mutated allele and one either intermediate (IA, 27-35 CAG repeats) or…Down-regulation of miR-9* in the peripheral leukocytes of Huntington’s Disease patients
Objective: To determine whether the alterations of microRNA expression in central nervous tissues can be detected in peripheral leukocytes in Huntington's disease (HD) patients. Background: Huntington’s…The neural correlates of apathy in premanifest and manifest Huntington’s disease: A cross-sectional multimodal imaging study
Objective: To delineate the brain correlates of apathy severity by means of glucose metabolism (18-FDG PET), grey-matter (GM) and white-matter (WM; FA-DTI) changes and relations…Screening of cognitive impairment in Huntington’s disease with the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)
Objective: To explore the psychometric properties of the PD-CRS as compared to two commonly used measures (the MMSE and the UHDRS Cognitive score) for detecting…Predictors for psychosis in Huntington’s disease: preliminary analysis of the Enroll-HD database.
Objective: To evaluate predictors for psychosis in HD. Background: Behavioral problems are present across all stages of HD, even preceding the development of the motor…Examining central cognitive processing speed as an early marker of Huntington’s disease (HD) onset
Objective: To examine central processing speed as an early marker of Huntington’s disease (HD) onset using the Computerized Test of Information Processing (CTiP). Background: The CTiP,…Huntington’s Disease: Determinants for Cognitive Disease Progression – A Proposed Model
Objective: To develop a conceptual model to determine the rate of cognition impairment in Huntington's disease manifest patients and to identify the factors that influence…Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation
Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…Salivary biomarkers for Huntington’s disease (HD)
Objective: The objective of the current study was to assess the potential for saliva to serve as a biospecimen for accessible biomarkers for Huntington’s disease…The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine in Huntington Disease (HD) over long term exposure. Background: In a randomized, double-blind, controlled trial (First-HD),…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.